Hydroxy Camptothecine (10-Hydroxycamptothecin, Hydroxycamptothecine) is a cell-permeable powerful DNA topoisomerase I inhibitor. It has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.
10-HCPT has an inhibitory effect on phosphorylation of histone H1 and H3 in murine hepatoma cells and also exhibits a differentiation inducing effect in human HepG2 cells. 10-HCPT inhibits the cell growth, reduces the cell viability and disturbs the cell cycle distribution of human colon cancer cell line Colo 205. It induces cell cycle arrest in the G2/M phase[1].
10-HCPT can be safely orally administered and, alternatively, a low-dose long-term treatment[1]. Prolonged elimination of HCPT in vivo may have a significant impact on its therapeutic effects. HCPT is metabolized to its carboxylate form and glucuronides. Dose-dependent toxicity is observed with i.v. administration of HCPT[2].
[1] Ping YH, et al. Oncol Rep. 2006, 15(5):1273-9. [2] Zhang R, et al. Cancer Chemother Pharmacol. 1998, 41(4):257-67.
















